Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher (NYSE: DHR) has launched a collaboration with Johns Hopkins University to develop new methods for diagnosing mild Traumatic Brain Injury (TBI) using blood-based biomarkers. The partnership aims to improve the detection of specific biomarkers found in blood when brain cells are damaged, potentially leading to earlier and more precise diagnosis of TBI and improved treatment outcomes. The research, led by experts from Johns Hopkins School of Nursing and Johns Hopkins Medicine, leverages technology from Beckman Coulter Diagnostics, a Danaher subsidiary.
Danaher will have its President and CEO present at the Bank of America Securities Healthcare Conference in Las Vegas on May 14, 2024. The event will be webcasted on the company's website.
Danaher (NYSE: DHR) declared a regular quarterly cash dividend of $0.27 per share for its common stock. The dividend will be paid on July 26, 2024, to shareholders of record on June 28, 2024.
Curiox Biosystems and Beckman Coulter Life Sciences have announced a partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry, combining C-FREE™ technology with DURA Innovations. The collaboration aims to address challenges in standardization, automation, and reproducibility, paving the way for advancements in research and healthcare.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.